NCT02663323Unknown不适用
MeRes-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions
Meril Life Sciences Pvt. Ltd.8 个研究点 分布在 5 个国家目标入组 64 人开始时间: 2016年2月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 64
- 试验地点
- 8
- 主要终点
- Primary Clinical Endpoint: Proportion of population reporting with Major Adverse Cardiac Event at 6 months from the day of index procedure.
研究概览
简要总结
MeRes-1 Extend study is designed as prospective, multinational, multicentre, single arm, open label, pilot study to assess the safety and performance of the MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System (BRS) in subjects with de novo native coronary artery lesions. 64 subjects will be enrolled from the 8 centers located in Asia Pacific, Europe, Brazil and South Africa. Primary outcome of study will be Proportion of population reporting Major Adverse Cardiac Events at 6 months from the day of index Procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria:
- •Male or female subjects ≥ 18 years of age
- •Subject is able to sign written Informed Consent Form (ICF)
- •Subjects with symptomatic myocardial ischemia, chronic stable angina
- •The patient has planned intervention of a single de novo lesion in native epicardial vessel
- •Subject who is an acceptable candidate for Coronary Artery Bypass Grafting (CABG)
- •Subject is not participating in any other clinical investigation/study and agrees not to participate in any other clinical investigation/study for a period of 3 years following the index procedure.
- •Subject must agree to undergo all clinical investigation plan-required follow-up visits, angiograms and OCT as per protocol.
- •Angiographic Inclusion Criteria:
- •Subject with maximum two treatable de novo lesions located maximum one per native epicardial vessel located in major artery or branch, with reference vessel diameter between 2.75, 3.00 and 3.5 mm by on line QCA.
- •Target lesion length ≤ 20 mm.
- •Subjects with Lesion(s), with a visually estimated stenosis of ≥ 50% and < 100% with a TIMI flow of ≥ 1.
排除标准
- •General Exclusion Criteria:
- •Subjects unable to provide written informed consent.
- •Pregnant or nursing mother and those who plan pregnancy during the clinical investigation (female patients must have a negative pregnancy test done within 7 days prior to the index procedure and effective contraceptive must be used during participation in this clinical investigation).
- •Subjects with known allergy to Poly-L-Lactide (PLLA), Poly-D,L-Lactide (PDLLA), Sirolimus (Rapamycin) or its any analog or derivative, clopidogrel, ticlopidine, prasugrel, contrast media, platinum, ticagrelor and any drug in dual antiplatelet therapy including aspirin, both heparin and bivalirudin.
- •Subject diagnosed with Acute Myocardial Infarction (AMI) within 7 days preceding the index procedure, as indicated by elevated levels of cardiac enzymes and/or ST segment changes in Electro Cardio Gram (ECG).
- •Subject with history of previous revascularization procedures including CABG and Percutaneous Coronary Intervention (PCI).
- •Subject with vascular aneurysms, cardiac arrhythmias, congestive cardiac failure having LVEF < 30%, cardiac tamponade.
- •Recipient of an organ in an organ transplant procedure or is on a waiting list for any organ transplant.
- •Subjects receiving immunosuppression therapy or having known immunosuppressive or autoimmune disease.
- •Subjects with history of stroke, Cerebro Vascular Accident (CVA) or Transient Ischemic neurological Attack (TIA). Patients with renal insufficiency where creatinine levels are more than 1.3 mg/dl, known aplastic anaemia, chronic liver disease, platelet count <100,000 cells/mm3, a WBC of < 3,000 cells/mm
- •Subjects planned for elective surgery within the first 12 months after the procedure that will require discontinuing dual antiplatelet therapy
- •Subject has a history of bleeding diathesis or coagulatory disease, refuses blood transfusion, significant gastrointestinal or urinary bleed within the past 12 months.
- •Subject having extensive peripheral vascular disease that precludes safe 6F sheath insertion.
- •Subject having a history of paradoxical exercise induced vasoconstriction that is consistent with myocardial bridging in the coronary anatomy.
- •Subjects participating in another clinical investigation.
- •Subjects with short life expectancy such as cancer, Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS), or other co-morbid conditions that would limit compliance with the follow-up schedule of the study.
- •Angiographic Exclusion Criteria:
- •Subjects who are non-candidates for PCI.
- •Any of the target lesions meets any of the following criteria:
- •Aorto-ostial location (within 3 mm)
- •Lesion located in left main coronary artery
- •Lesion located within 2 mm of origin of the LAD or LCx
- •Lesion that involves a bifurcation with a side branch ≥ 2mm in diameter and ostial lesion > 40% stenosed by visual estimation or side branch requiring intervention
- •Total occlusion (TIMI Flow 0), prior to wire crossing
- •Extreme tortuosity proximal to or within the lesion
- •Lesions having heavy calcification
- •Extreme angulation (≥ 90 %) proximal to or within the lesion
- •Evidence of previous revascularization:
- •Previous PCI with or without restenosis from previous intervention
- •Arterial or venous graft with or without lesion located within the graft or distal to a diseased arterial or saphenous vein graft
- •The target vessel contains visible thrombus.
- •Another (clinically significant or potentially significant) lesion left untreated within target vessels (including side branch) or another significant vessel.
- •Subject requiring or potentially requiring interventional procedures other than pre-dilatation and study device implantation and post dilatation.
结局指标
主要结局
Primary Clinical Endpoint: Proportion of population reporting with Major Adverse Cardiac Event at 6 months from the day of index procedure.
时间窗: 6 Month
Primary Safety Endpoint: Proportion of population reporting with Ischemia Driven Major Adverse Cardiac Event (ID MACE) reporting at 6 months (180 days) from the day of index procedure
时间窗: 6 Month
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
已完成
3 期
Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate CancerCastrate-resistant Prostate CancerNCT01824342Amgen18
终止
1 期
A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)MPS IV AMucopolysaccharidosis IVAMorquio A SyndromeNCT01242111BioMarin Pharmaceutical20
招募中
3 期
Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 StudiesHeterozygous or Homozygous Familial HypercholesterolemiaNCT05682378Novartis Pharmaceuticals195
已完成
2 期
Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label ExtensionTourette Syndrome in ChildrenTourette Syndrome in AdolescenceNCT04114539Emalex Biosciences Inc.124
已完成
3 期
A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT01772316Hoffmann-La Roche47